Table 1.

Characteristics of 9 studies eligible for inclusion in meta-analysis

Studies	ARG/PG (or control group)	Inclusion criteria of IUGR fetuses (Fetal weight)	Disease of pregnancy	Maternal age (wk, ARG/ PG)	Gestational age at entry (wk, ARG/ PG)	Daily dose and supplement type	Course of treatment
Sieroszewski et al. 2004 [14]	78/30	Below 10th percentile for GA	NA	27.1 ± 5.2/29.5 ± 7.4	29.5 ± 2.7/31.7 ± 3.6	3 g/d, oral	20 days
Xiao and Li 2005 [8]	30/36	Below 10th percentile for GA	NA	27.0 ± 3.6/27.4 ± 3.1	33.03 ± 2.59/33.06 ± 2.43	20 g/day, intravenous	7 days
Rytlewski et al. 2006 [15]	30/31	Below 10th percentile for GA	preeclampsia	29.3 ± 6.7/29.2 ± 5.9	29.3 ± 3.42/29.1 ± 3.41	3 g/d, oral	Until delivery
Dear et al. 2007 [9]	42/27	Below 10th percentile for GA	Gestational hypertension	28 ± 5/28 ± 4	31.09 ± 2.98/29.88 ± 3.22	3 g/d, oral	Until delivery
Ropacka et al. 2007 [12]	24/17	Below 10th percentile for GA	NA	28.7 ± 5.9/28.7 ± 3.8	31.2 ± 3.1/29.7 ± 3.4	3 g/d, oral	Until delivery
Zhang et al. 2007 [11]	35/33	Below 10th percentile for GA	Gestational hypertension	NA	NA	20 g/d, intravenous	14 days
Winer et al. 2009 [10]	21/22	Below 3rd percentile for GA	Preeclampsia,or other disease	28.2 ± 5.9/29.3 ± 4.2	28.0 ± 2.0/27.7 ± 2.1	14 g/d, oral	Until delivery
Shen and Hua 2011 [13]	30/30	Below 10th percentile for GA	NA	NA	NA	15 g/d, intravenous	NA
Singh et al. 2014 [16]	30/30	Below 10th percentile for GA	NA	25.47 ± 4.3/25.17 ± 4.3	33.13 ± 2.9/33.0 ± 2.3	3 g/d, oral	21 days

ARG L-Arginine treatment group, PG placebo group, GA gestational age, NA not available